Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals (KERX) to Buy

Article Stock Quotes (1) Comments (0)

Ladenburg Thalmann upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Buy, new price target of $3.00.

For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.

Shares of Keryx Biopharmaceuticals closed at $1.45 yesterday, with a 52 week range of $1.28-$5.55.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
• Stifel Nicolaus Upgrades Dice Holdings (DHX) to Buy
• UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind

Create E-mail Alert Related Categories

Upgrades

Related Entities

Ladenburg Thalmann Financial Services

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?